Aurinia Pharmaceuticals Inc. AUPH

What this company does

Aurinia sells LUPKYNIS to two specialty pharmacies and a specialty distributor in the United States, and sells LUPKYNIS inventory to its collaboration partner, Otsuka Pharmaceutical Co., Ltd., for the European and Japanese market. In January 2021, the Company introduced LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. In December 2020, Aurinia entered into a collaboration and licensing agreement with Otsuka to develop and commercialize oral voclosporin in Japan, the European Union, the United Kingdom, Switzerland, Russia, Norway, Belarus, Iceland, Liechtenstein and Ukraine. Aurinia is also developing aritinercept, a dual inhibitor of B cell-activating factor and a proliferation-inducing ligand for the potential treatment of autoimmune diseases. As of February 25, 2026, it had 128 full-time equivalent employees. Aurinia is organized as a corporation under the Business Corporations Act (Alberta), has one wholly owned subsidiary, Aurinia Pharma U.S., Inc., a Delaware corporation, and its principal executive office is located at #140, 14315 - 118 Avenue, Edmonton, Alberta, Canada.

Written from the business description in Aurinia Pharmaceuticals Inc.'s annual report to the U.S. Securities and Exchange Commission, filed 26 February 2026. Every sentence was checked against that document before publication.